We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sepsis Host-Response PCR Test Enables Early Targeted Therapies

By LabMedica International staff writers
Posted on 29 Mar 2023
Print article
Image: The AcuSept PCR Test is a sepsis host-response blood test based on specific biomarkers (Photo courtesy of Pexels)
Image: The AcuSept PCR Test is a sepsis host-response blood test based on specific biomarkers (Photo courtesy of Pexels)

Sepsis is a leading cause of hospital deaths, resulting in significant human and economic costs. The lack of effective antimicrobials to treat sepsis leads to the death of 11 million people annually. Delayed diagnosis of sepsis can increase the risk of developing septic shock by 4-9% per hour. Early identification of sepsis in patients with ambiguous symptoms can help healthcare professionals provide timely targeted treatment, even before the results of confirmatory tests such as microbiology cultures are available. Now, a host (patient) immune response test can identify 19 mRNA biomarkers of infection, sepsis and septic shock, and can also be used to monitor patient response to treatment.

AcuSept from Acumen Diagnostics Pte. Ltd. (Singapore) is a sepsis host-response blood test based on specific biomarkers that evaluates the host's immune response dysregulation during systemic infection and sepsis by analyzing the gene expression signature of 19 leukocyte mRNA biomarkers, using RT-PCR. The sepsis PCR-based diagnostic test generates results within five hours of patient sample collection.

AcuSept results provide valuable information about infection and sepsis risk and progression. The test can diagnose culture-negative sepsis, which can be difficult to detect using traditional microbiology culture tests that are slower and less sensitive. By overcoming these limitations, AcuSept enables patient triage and monitoring and can be used as a complementary tool to clinical assessments and other diagnostic parameters. AcuSept can inform the selection of appropriate treatment bundles based on the severity risk of sepsis, from early sepsis to severe sepsis and septic shock, and allows for the monitoring of patient response to treatment.

Acumen's clinical studies have demonstrated that AcuSept outperforms other single-biomarker tests in detecting sepsis, and is highly effective in diagnosing culture-negative sepsis. The test's superior positive and negative predictive values enable it to detect infection in patients, providing supplementary information to pathogen identification tests. With AcuSept test results, doctors can gain crucial insights into a patient's condition, allowing for more comprehensive assessments and targeted treatment decisions with greater speed.

Related Links:
Acumen Diagnostics 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The fastGEN BCR::ABL1 Cancer kit offers a way to personalize treatment strategies for leukemia (Photo courtesy of BioVendor MDx)

First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment

The BCR::ABL1 fusion gene plays a key role in the pathogenesis of several blood cancers, particularly chronic myeloid leukemia (CML). This gene results from a chromosomal translocation that causes constitutive... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The new method is quick and easy, and can also be used by non-medical personnel. (Photo courtesy of Zoratto et al. Advanced Science 2024, edited)

New Blood Test Device Modeled on Leeches to Help Diagnose Malaria

Many individuals have a fear of needles, making the experience of having blood drawn from their arm particularly distressing. An alternative method involves taking blood from the fingertip or earlobe,... Read more